Biosolution Co.Ltd
Bio Solution Co.,Ltd. develops, manufactures, and sells cell therapy products worldwide. The company offers CartiLife, an autologous chondrocyte cell-based therapy for the restoration of symptomatic and structural complications caused by articular cartilage defects; KeraHeal-Allo, a thermosensitive hydrogel-type allogenic keratinocyte cell-therapy product to promote re-epithelialization of deep 2… Read more
Biosolution Co.Ltd (086820) - Total Liabilities
Latest total liabilities as of September 2025: ₩36.25 Billion KRW
Based on the latest financial reports, Biosolution Co.Ltd (086820) has total liabilities worth ₩36.25 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Biosolution Co.Ltd - Total Liabilities Trend (2015–2024)
This chart illustrates how Biosolution Co.Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Biosolution Co.Ltd Competitors by Total Liabilities
The table below lists competitors of Biosolution Co.Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Firstec
KO:010820
|
Korea | ₩317.77 Billion |
|
Tjk Machinery Tianjin Co Ltd
SHE:300823
|
China | CN¥308.64 Million |
|
First Steamship Co Ltd
TW:2601
|
Taiwan | NT$20.68 Billion |
|
First Farmers and Merchants Corporation
PINK:FFMH
|
USA | $1.62 Billion |
|
Bally's Corp
NYSE:BALY
|
USA | $7.03 Billion |
|
QuickLogic Corporation
NASDAQ:QUIK
|
USA | $22.34 Million |
|
Wave Cyber Shanghai Co Ltd
SHG:688718
|
China | CN¥141.72 Million |
Liability Composition Analysis (2015–2024)
This chart breaks down Biosolution Co.Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.55 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.38 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.58 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biosolution Co.Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biosolution Co.Ltd (2015–2024)
The table below shows the annual total liabilities of Biosolution Co.Ltd from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩36.21 Billion | -27.90% |
| 2023-12-31 | ₩50.22 Billion | +4.72% |
| 2022-12-31 | ₩47.96 Billion | -2.91% |
| 2021-12-31 | ₩49.39 Billion | +1475.96% |
| 2020-12-31 | ₩3.13 Billion | -15.54% |
| 2019-12-31 | ₩3.71 Billion | -2.39% |
| 2018-12-31 | ₩3.80 Billion | +28.41% |
| 2017-12-31 | ₩2.96 Billion | +9.73% |
| 2016-12-31 | ₩2.70 Billion | +12.64% |
| 2015-12-31 | ₩2.40 Billion | -- |